Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Common Equity (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Common Equity for 11 consecutive years, with $518.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 147.41% year-over-year to $518.4 million, compared with a TTM value of $518.4 million through Dec 2025, up 147.41%, and an annual FY2025 reading of $518.4 million, up 147.41% over the prior year.
  • Common Equity was $518.4 million for Q4 2025 at Wave Life Sciences, up from $124.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $518.4 million in Q4 2025 and bottomed at -$51.7 million in Q2 2023.
  • Average Common Equity over 5 years is $67.9 million, with a median of $30.4 million recorded in 2021.
  • The sharpest move saw Common Equity crashed 65398.11% in 2023, then skyrocketed 4105.35% in 2025.
  • Year by year, Common Equity stood at $32.5 million in 2021, then crashed by 238.75% to -$45.1 million in 2022, then soared by 187.89% to $39.6 million in 2023, then skyrocketed by 428.68% to $209.5 million in 2024, then soared by 147.41% to $518.4 million in 2025.
  • Business Quant data shows Common Equity for WVE at $518.4 million in Q4 2025, $124.5 million in Q3 2025, and $139.3 million in Q2 2025.